Nathalie Cartier obtained her Medical degree from the University René Descartes in Paris where she completed her residency and specialized in Pediatrics. She became Research Director at INSERM and associate Professor at University Descartes.
Her research interest focuses on the development of gene therapy approaches for neurodegenerative diseases. She developed with Patrick Aubourg the pioneer work on hematopoietic stem cell gene therapy for X-linked Adrenoleukodystrophy, first clinical trial using an HIV-derived lentiviral vector. Her research group (INSERM U1169) located in Paris at the CEA (Commission for Atomic Energy), in the Molecular Imaging center (MIRCen) evaluates gene therapy for Huntington ‘s and Alzheimer’s diseases based on modulation of brain lipid metabolism.
Her work includes all translation steps from preclinical proof of concept in animal models to clinical application in human patients: vector development, animal models characterization, gene transfer and validation in animal models, submission of clinical application to regulatory agencies, clinical trials in human patients. Nathalie Cartier is Co-PI in gene therapy clinical trials for Adrenoleukodystrophy and metachromatic leukodystrophy (opened in 2014)
Nathalie Cartier is member of the Scientific Committee of INSERM. She is Vice President of the the scientific committee of the Fondation Maladies Rares, and current President of the European Society for Gene and Cell Therapy (ESGCT) and has been President of the French Society for Cell and Gene Therapy.